These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 32872621)

  • 1. The Microbiome as a Therapeutic Target for Multiple Sclerosis: Can Genetically Engineered Probiotics Treat the Disease?
    Kohl HM; Castillo AR; Ochoa-Repáraz J
    Diseases; 2020 Aug; 8(3):. PubMed ID: 32872621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis.
    Bianchimano P; Britton GJ; Wallach DS; Smith EM; Cox LM; Liu S; Iwanowski K; Weiner HL; Faith JJ; Clemente JC; Tankou SK
    Microbiome; 2022 Oct; 10(1):174. PubMed ID: 36253847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut-Microbiota, and Multiple Sclerosis: Background, Evidence, and Perspectives.
    Altieri C; Speranza B; Corbo MR; Sinigaglia M; Bevilacqua A
    Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiome and multiple sclerosis: New insights and perspective.
    Esmaeil Amini M; Shomali N; Bakhshi A; Rezaei S; Hemmatzadeh M; Hosseinzadeh R; Eslami S; Babaie F; Aslani S; Torkamandi S; Mohammadi H
    Int Immunopharmacol; 2020 Nov; 88():107024. PubMed ID: 33182024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue.
    Kirby TO; Ochoa-Repáraz J
    Med Sci (Basel); 2018 Aug; 6(3):. PubMed ID: 30149548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut Microbiota in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Current Applications and Future Perspectives.
    Chu F; Shi M; Lang Y; Shen D; Jin T; Zhu J; Cui L
    Mediators Inflamm; 2018; 2018():8168717. PubMed ID: 29805314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome.
    Camara-Lemarroy CR; Metz LM; Yong VW
    World J Gastroenterol; 2018 Oct; 24(37):4217-4223. PubMed ID: 30310254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of gut-brain axis and use of probiotics as a treatment strategy for multiple sclerosis.
    Kumar N; Sahoo NK; Mehan S; Verma B
    Mult Scler Relat Disord; 2023 Mar; 71():104547. PubMed ID: 36805171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary Modulation of Intestinal Microbiota: Future Opportunities in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
    Fan Y; Zhang J
    Front Microbiol; 2019; 10():740. PubMed ID: 31040833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bidirectional association between the gut microbiota and CNS disease in a biphasic murine model of multiple sclerosis.
    Colpitts SL; Kasper EJ; Keever A; Liljenberg C; Kirby T; Magori K; Kasper LH; Ochoa-Repáraz J
    Gut Microbes; 2017 Nov; 8(6):561-573. PubMed ID: 28708466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The "Gut Feeling": Breaking Down the Role of Gut Microbiome in Multiple Sclerosis.
    Freedman SN; Shahi SK; Mangalam AK
    Neurotherapeutics; 2018 Jan; 15(1):109-125. PubMed ID: 29204955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut Microbiota Interventions With
    Chen H; Ma X; Liu Y; Ma L; Chen Z; Lin X; Si L; Ma X; Chen X
    Front Immunol; 2019; 10():1662. PubMed ID: 31428083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probiotics and Commensal Gut Microbiota as the Effective Alternative Therapy for Multiple Sclerosis Patients Treatment.
    Dziedzic A; Saluk J
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiome Methods in Experimental Autoimmune Encephalomyelitis.
    Daberkow DP; Hoffman K; Kohl HM; Long T; Kirby TO; Ochoa-Repáraz J
    Curr Protoc; 2021 Dec; 1(12):e314. PubMed ID: 34870901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis.
    Calvo-Barreiro L; Eixarch H; Ponce-Alonso M; Castillo M; Lebrón-Galán R; Mestre L; Guaza C; Clemente D; Del Campo R; Montalban X; Espejo C
    Cells; 2020 Apr; 9(4):. PubMed ID: 32272791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease.
    Lombardi VC; De Meirleir KL; Subramanian K; Nourani SM; Dagda RK; Delaney SL; Palotás A
    J Nutr Biochem; 2018 Nov; 61():1-16. PubMed ID: 29886183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoregulatory Effects of Tolerogenic Probiotics in Multiple Sclerosis.
    Atabati H; Yazdanpanah E; Mortazavi H; Bajestani SG; Raoofi A; Esmaeili SA; Khaledi A; Saburi E; Afshari JT; Sathyapalan T; Moghaddam AS; Sahebkar A
    Adv Exp Med Biol; 2021; 1286():87-105. PubMed ID: 33725347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis.
    Calvo-Barreiro L; Eixarch H; Montalban X; Espejo C
    Autoimmun Rev; 2018 Feb; 17(2):165-174. PubMed ID: 29191793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impacts of microbiome metabolites on immune regulation and autoimmunity.
    Haase S; Haghikia A; Wilck N; Müller DN; Linker RA
    Immunology; 2018 Jun; 154(2):230-238. PubMed ID: 29637999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-chain fatty acids and gut microbiota in multiple sclerosis.
    Melbye P; Olsson A; Hansen TH; Søndergaard HB; Bang Oturai A
    Acta Neurol Scand; 2019 Mar; 139(3):208-219. PubMed ID: 30427062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.